People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CoLucid Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $60.0M | $1.3B | 2009 |
| Aldeyra Therapeutics, Inc. | — | Biotechnology | Series A | $24.6M | $361.5M | 2015 |
| Veracyte, Inc. | — | Other Health Care | Series A | $22.1M | $258.2M | 2014 |
| Somaxon Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $6.0M | $185.8M | 2009 |
| Altea Therapeutics Corp | — | Biotechnology | Seed | $3.7M | $30.4M | 2009 |
Jesse I. Treu at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jesse I. Treu on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| David F Hale | 1 | 16 |
| Brook Byers | 1 | 13 |
| Fred Cohen | 1 | 12 |
| Brian G. Atwood | 1 | 8 |
| Todd Brady | 1 | 7 |
| Kurt Von Emster | 1 | 6 |
| Anthony Evnin | 1 | 6 |
| Brian Atwood | 1 | 6 |
| Jonathan T. Lord | 1 | 5 |
| Alan Smith | 1 | 4 |
| Gerald Cagle | 1 | 4 |
| Jesse Treu | 1 | 4 |
| Richard W. Pascoe | 1 | 4 |
| Samuel D. Colella | 1 | 4 |
| Anthony B. Evnin | 1 | 4 |
| Evan Jones | 1 | 4 |
| Gary Phillips | 1 | 4 |
| Ben Bronstein | 1 | 4 |
| Shelly D. Guyer | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.